Related Experiment Video
Updated: Sep 30, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis
Gabriela Spencer-Bonilla1, Joyce N Njoroge2, Keon Pearson1
1Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Insights
Transthyretin amyloid cardiomyopathy (ATTR-CM) affects older adults and Black individuals disproportionately. Addressing disparities in diagnosis and treatment is crucial for improving outcomes in this underrepresented population.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and often fatal condition.
- ATTR-CM is increasingly recognized as a significant cause of heart failure, particularly in older adults.
- Historically underestimated, ATTR-CM prevalence is higher in specific demographics, including individuals of African descent.
Purpose of the Study:
- To review current knowledge on racial and ethnic disparities in ATTR-CM diagnosis and management.
- To highlight the disproportionate impact of ATTR-CM on older adults and people of African descent.
- To examine existing gaps in clinical data and trial representation for minority populations.
Main Methods:
- Literature review of existing studies on ATTR-CM.
- Analysis of demographic data concerning ATTR-CM prevalence and diagnosis.
- Examination of clinical trial participation rates across racial and ethnic groups.
Main Results:
- ATTR-CM is more prevalent in older adults and people of African descent than previously thought.
- Significant geographic variations exist in ATTR-CM diagnosis.
- Black patients are underrepresented in clinical trials and data sets for ATTR-CM.
- Socioeconomic factors, including cost and access to therapies, exacerbate disparities.
Conclusions:
- Earlier identification of ATTR-CM in primary care settings can improve outcomes for all patient groups.
- Future clinical trials must prioritize enrollment of a higher proportion of Black patients.
- Enhanced strategies are needed to improve access to disease-modifying therapies for affected racial and ethnic minority groups.
Purpose Of Review:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease that disproportionately affects older adults and people of African descent. This review discusses current knowledge regarding racial and ethnic disparities in the diagnosis and management of ATTR-CM.
Recent Findings:
Historically, ATTR-CM was thought to be a rare cause of heart failure. Recent evidence has shown that ATTR-CM is more common among older adults, men, and people of African descent. In addition, significant geographic variation exists in the identification of amyloid cardiomyopathy. Despite the high burden of ATTR-CM among Black individuals, most clinical data for ATTR-CM are from North America and Europe. Moreover, only a minority of clinical trial participants thus far have been Black patients. In addition to racial differences, socioeconomic disparities may be further compounded by the potentially prohibitive cost and limited accessibility of disease-modifying ATTR therapies.
Summary:
ATTR-CM is an important cause of heart failure that disproportionately affects people of African descent. Efforts to promote earlier identification of ATTR-CM in general practice will likely improve clinical outcomes for all groups. Future trials should strive to enroll a higher proportion of Black patients. Furthermore, enhanced efforts are warranted to improve treatment accessibility among racial and ethnic minority groups that may be more likely to be affected by ATTR-CM.
More Related Videos
09:37A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
16:02Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Stereotypes, Prejudice, and Discrimination